Sunday, June 11, 2023 11:02:03 PM
OJ,
Thanks for the reply.
We should not have any reservations about the quality of evidence from Dr. Bosch's presentation. NWBO has been collaborating with world-renowned scientists. Take a look at the members in the advisory committee. Take a look at Dr. Subbiah's resume, the guy who published papers with the inventor of checking point inhibitors, James Allison, a Noble Prize winner. Take a look at Linda Liau's resume.
Tens of patients with various types of solid tumors received DCVax-L treatment through compassionate use. If I am not mistaken, compassionate use is reviewed by FDA on case-by-case basis. If there were no effects, would FDA keep approving it?
I doubt anyone here has a Ph.D. specifically in dendritic cells. Therefore no one here is equipped to question the scientific validity of the data.
Dr. Bosch just showed us the vaccine can be loaded with antigens of various solid tumors. Without a doubt, he would following the steps similar to what Antonios did in his dissertation under Dr. Liau's guidance.
https://escholarship.org/content/qt0t37x26s/qt0t37x26s.pdf
Thanks for the reply.
We should not have any reservations about the quality of evidence from Dr. Bosch's presentation. NWBO has been collaborating with world-renowned scientists. Take a look at the members in the advisory committee. Take a look at Dr. Subbiah's resume, the guy who published papers with the inventor of checking point inhibitors, James Allison, a Noble Prize winner. Take a look at Linda Liau's resume.
Tens of patients with various types of solid tumors received DCVax-L treatment through compassionate use. If I am not mistaken, compassionate use is reviewed by FDA on case-by-case basis. If there were no effects, would FDA keep approving it?
I doubt anyone here has a Ph.D. specifically in dendritic cells. Therefore no one here is equipped to question the scientific validity of the data.
Dr. Bosch just showed us the vaccine can be loaded with antigens of various solid tumors. Without a doubt, he would following the steps similar to what Antonios did in his dissertation under Dr. Liau's guidance.
https://escholarship.org/content/qt0t37x26s/qt0t37x26s.pdf
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
